Results 71 to 80 of about 40,304 (164)

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani   +7 more
wiley   +1 more source

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors

open access: yeseLife, 2019
Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a promising new class of antiretroviral agents that disrupt proper viral maturation by inducing hyper-multimerization of IN.
Pratibha C Koneru   +14 more
doaj   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

open access: yesHIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning   +16 more
wiley   +1 more source

Insights into the Functions of a Prophage Recombination Directionality Factor

open access: yesViruses, 2012
Recombination directionality factors (RDFs), or excisionases, are essential players of prophage excisive recombination. Despite the essentially catalytic role of the integrase in both integrative and excisive recombination, RDFs are required to direct ...
Mireille Ansaldi   +3 more
doaj   +1 more source

Prior PrEP use and discontinuation in individuals newly diagnosed with HIV

open access: yesHIV Medicine, EarlyView.
Abstract Background In settings with high uptake of HIV pre‐exposure prophylaxis (PrEP), an increasing proportion of individuals newly diagnosed with HIV report prior PrEP exposure. Understanding patterns of PrEP use, discontinuation and adherence in such settings is essential to inform future HIV prevention strategies.
Rohan Saini   +15 more
wiley   +1 more source

Screening for bone health in older people with HIV: Uptake and outcomes from a large UK outpatient HIV service

open access: yesHIV Medicine, EarlyView.
Abstract Objectives Bone health is negatively affected in people with HIV, and the risks of osteoporosis and fragility fractures are increased. The objective of this study was to describe the characteristics of those accessing bone health screening and identify factors associated with osteoporosis.
Rhys Nicholas   +3 more
wiley   +1 more source

Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States

open access: yesHIV Medicine, EarlyView.
Abstract Objectives Dolutegravir (DTG) has been associated with weight gain in women with HIV, Black people with HIV and people with HIV60 years. This study aimed to characterise DTG population pharmacokinetics (PopPK) in a diverse population including these sub‐populations.
Adrian Khoei   +29 more
wiley   +1 more source

Comparison Between Several Integrase-defective Lentiviral Vectors Reveals Increased Integration of an HIV Vector Bearing a D167H Mutant

open access: yesMolecular Therapy: Nucleic Acids, 2014
HIV-1 derived vectors are among the most efficient for gene transduction in mammalian tissues. As the parent virus, they carry out vector genome insertion into the host cell chromatin.
Muhammad Qamar Saeed   +17 more
doaj   +1 more source

UltRaSoUnd‐guided evaLuAtion of metabolic health in a cohort of midlife women with HIV: The URSULA study

open access: yesHIV Medicine, EarlyView.
Abstract Objectives We aimed to determine the prevalence of metabolic disorders, liver steatosis and metabolic dysfunction‐associated steatotic liver disease (MASLD) in a cohort of middle‐aged women with HIV (WoWH) and to explore associations between liver steatosis, visceral fat depots and carotid atherosclerosis.
Mariacristina Poliseno   +13 more
wiley   +1 more source

Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study

open access: yesHIV Medicine, EarlyView.
Abstract Objectives We have shown that semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), is a highly effective therapy for metabolic dysfunction‐associated steatotic liver disease (MASLD) in people with HIV (PWH). The OWLiver® metabolomics algorithms allow non‐invasive MASLD severity staging without liver biopsy, but the use of ...
Jordan E. Lake   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy